All entries for: Rare Disease

June 15, 2026

Sernova Biotherapeutics

Investment: Designated

prevention of diabetes due to total pancreatectomy

Disease Area: Rare Diseases
June 11, 2026

Shanghai Simnova Biotechnology Co. Ltd.

Investment: Designated

treatment of small cell lung cancer

Disease Area: Rare Diseases
June 11, 2026

Alkermes Inc.

Investment: Designated

treatment of idiopathic hypersomnia

Disease Area: Rare Diseases
June 11, 2026

GRT Therapeutics Inc.

Investment: Designated

treatment of Duchenne muscular dystrophy

Disease Area: Rare Diseases
June 10, 2026

Beren Therapeutics

Investment: Later Stage VC

Beren Therapeutics raised $300 million to support the potential commercial launch of adrabetadex, an FDA Breakthrough Therapy-designated cyclodextrin therapy under Priority Review for the treatment of infantile-onset Niemann-Pick disease type C, a rare and rapidly fatal pediatric neurodegenerative disorder.

Disease Area: Rare Diseases
June 9, 2026

Ratio Therapeutics Inc.

Investment: Designated

treatment of soft tissue sarcoma

Disease Area: Rare Diseases
June 8, 2026

Langxin Qisheng (Suzhou) Biopharmaceutical Co. Ltd.

Investment: Designated

treatment of PROM1-associated retinal dystrophy

Disease Area: Rare Diseases
June 8, 2026

Kalevala Therapeutics Inc.

Investment: Designated

treatment of alternating hemiplegia

Disease Area: Rare Diseases
June 8, 2026

Infinant Health

Investment: Later Stage VC

Infinant Health raised $39.25 million to advance INF108, an FDA-designated orphan drug and rare pediatric disease-designated live biotherapeutic for the prevention of necrotizing enterocolitis, a rare and life-threatening intestinal condition primarily affecting preterm infants.

Disease Area: Rare Diseases
June 8, 2026

City Therapeutics

Investment: Early Stage VC

City Therapeutics raised $99.5 million to advance CITY-FXI, a next-generation RNAi therapy in Phase 1 clinical development for the prevention of thromboembolic diseases including stroke and deep vein thrombosis, as well as CITY-RBP4, an RNAi candidate for Stargardt disease, a rare inherited form of juvenile macular degeneration.

Disease Area: Rare Diseases
Scroll to Top